Project Grant R34CA286803
Award Date
9/11/24
Completion Date
8/31/27
Dollars Obligated
$280K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Houston, TX 77204, USA
Similar Awards
This federal Project Grant award for $625,201 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a randomized factorial trial to evaluate the effectiveness of combining varenicline with nicotine lozenges and a smartphone medication adherence intervention to promote smoking cessation. The study aims to enroll 496 adult smokers and assess 7-day point prevalence abstinence at 26 weeks and medication adherence over the 13-week...
This federal Project Grant award for $399,891, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, funds a feasibility study to evaluate the use of the SensewHy, Inc. "SmonkeMon" wearable device for remotely monitoring smoking behavior and triggers among cancer survivors. The key products and services to be delivered under this Phase 1 SBIR project include: 1) assessing the feasibility of the SmonkeMon device for...
This Project Grant award for $515,632.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is aimed at ensuring the U.S. is fully prepared to maximize smoking cessation rates during and following the implementation of proposed cigarette product standards by the U.S. Food and Drug Administration (FDA). The key objectives are to: Estimate, for each U.S. state, the number of people who smoke (PWS) who will quit smoking and enroll in quitlines in the year...
The National Cancer Institute (NCI) awarded a 5-year, $757,913 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Fred Hutchinson Cancer Center in Seattle, Washington. The grant will fund a randomized controlled trial to determine whether providing a smoking cessation smartphone app (iCanQuit) in combination with free nicotine replacement therapy (NRT) is more effective and cost-effective for increasing biochemically verified 30-day smoking abstinence among...
The National Cancer Institute (NCI) awarded a $257,415 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Research Foundation for the State University of New York (RF SUNY) to develop an AI-enhanced smartphone app-based intervention for adolescent e-cigarette cessation. The goal is to create a scalable, cost-effective intervention that uses AI-assisted user profiling and personalized content to help adolescents quit e-cigarettes. The 3-year project will...
This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) will provide $661,139 to The Ohio State University to test the use of oral nicotine pouches as an alternative to cigarette smoking among rural Appalachian adults. The study will evaluate whether oral nicotine pouches are more effective than nicotine replacement therapy (NRT) in helping this population reduce or quit smoking, which contributes to high cancer rates in the region. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to Flik Therapeutics, Inc. to support the development of a novel FDA-regulated pharmacotherapy and multimodal nicotine cessation program. The goal is to create a more effective smoking cessation therapy compared to the current standard of care, which has low success rates. This Phase I proposal will fund the initial development of the...
This $316,873 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports the development and pilot testing of a smartphone app version of the evidence-based "Libre del Cigarrillo" smoking cessation intervention for Spanish-speaking individuals. The key goals are to: 1) adapt the existing validated printed smoking cessation intervention for Spanish-speakers into a smartphone app format, and 2) conduct a...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $452,540.00 to the Sloan-Kettering Institute for Cancer Research to investigate the use of electronic nose (e-nose) technology to predict and assess response to induction therapy and identify recurrence in patients with locally advanced non-small cell lung cancer. The research aims to evaluate volatile organic compounds in patient exhalates to improve the prediction and assessment of...
This $1,226,040 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to develop and test a culturally-tailored suite of smoking cessation resources for American Indian (AI) persons. The key products/services to be delivered include: Co-creating a culturally-aligned website, "Smokefree.gov for Natives", to serve as the landing page for AI-specific cessation content and resources. Conducting a randomized...